Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network-Reference-Cited by-同舟云学术

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network

Published:2021-06-28 Issue:18 Volume:127 Page:3413-3421
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Gay Francesca¹,Günther Andreas²,Offidani Massimo³,Engelhardt Monika⁴^ORCID,Salvini Marco¹,Montefusco Vittorio⁵,Patriarca Francesca⁶,Aquino Sara⁷,Pönisch Wolfram⁸,Spada Stefano¹,Schub Natalie²,Gentili Silvia⁹,Wäsch Ralph⁴,Corradini Paolo⁵,Straka Christian¹⁰,Palumbo Antonio¹,Einsele Hermann¹¹,Boccadoro Mario¹,Sonneveld Pieter¹²,Gramatzki Martin²^ORCID

Affiliation:

1. Myeloma Unit, Division of Hematology University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza Torino Italy

2. Division of Stem Cell Transplantation and Immunotherapy University of Kiel Kiel Germany

3. Hematology Clinic AOU Ospedali Riuniti di Ancona Ancona Italy

4. Department for Hematology and Oncology University of Freiburg, Faculty of Freiburg Freiburg Germany

5. Hematology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy

6. Hematology and Transplant Unit University of Udine Udine Italy

7. Ematologia e Centro Trapianti IRCCS Ospedale Policlinico San Martino Genova Italy

8. Department of Hematology University of Leipzig Leipzig Germany

9. UODS Ematologia AV3 Civitanova Marche Italy

10. Department of Hematology and Oncology Munich Clinic Schwabing Munich Germany

11. Department of Medicine II University Hospital of Würzburg Würzburg Germany

12. Department of Hematology Erasmus University Medical Center Cancer Institute Rotterdam The Netherlands

Funder

Mundipharma International

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33647

Reference48 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

3. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups

4. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

5. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity;British Journal of Pharmacology;2024-04-28

2. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

3. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

4. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy;Current Problems in Cardiology;2023-03

5. How I treat relapsed multiple myeloma;Blood;2022-05-12